Drug Profile
HBM 9302
Alternative Names: Anti-HER2-anti-CD3-antibody - Glenmark; GBR-1302; HBM-9302; ISB-1302Latest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals S.A.
- Developer Glenmark Pharmaceuticals S.A.; Harbour BioMed
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 13 Jul 2021 Discontinued - Phase-I for Gastric cancer in USA (IV) (Glenmark Pharmaceuticals pipeline, July 2021)
- 13 Jul 2021 Discontinued - Phase-I/II for HER2-positive-breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (Glenmark Pharmaceuticals pipeline, July 2021)
- 13 Jul 2021 Discontinued - Preclinical for Gastric cancer in China (IV) (Harbour Biomed pipeline, July 2021)